Streetbeat News

Stock Prices

NVAX

Novavax, Inc. (NASDAQ:NVAX) has seen a significant surge in its stock price following positive news about its COVID-19 vaccine. The FDA has completed the filing review of Novavax's Biologics License Application, setting a PDUFA review goal date for April 2025. The stock has risen over 300% in the past month and nearly 40% in the past five days, driven by high trading volume and a high short-interest ratio. Technical indicators suggest a strong bullish trend, although the stock is currently overbought.

Portfolio Pulse from Surbhi Jain

June 06, 2024 | 3:26 pm

FREY

FREYR Battery shares are trading lower following the announcement of leadership changes.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 3:22 pm

FIVE

Five Below, Inc. (NASDAQ:FIVE) shares are trading lower after the company reported worse-than-expected first-quarter earnings and cut guidance for the second quarter and full fiscal year. The company missed analyst estimates on both EPS and revenue, and several analysts have lowered their price targets.

Portfolio Pulse from Dylan Berman

June 06, 2024 | 3:20 pm

FLYE

Fly-E Group Inc. shares were halted on a circuit breaker to the upside, indicating a significant upward movement in the stock price.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 3:18 pm

ADBE

Adobe Inc. (NASDAQ: ADBE) has updated its terms and conditions for its apps, including Photoshop, causing backlash from professional users. The new terms grant Adobe extensive rights to access and use user content, sparking privacy concerns and calls to cancel subscriptions.

Portfolio Pulse from Michael Cohen

June 06, 2024 | 3:16 pm

ABUS

Barinthus Biotherapeutics presented updated data from two clinical trials in chronic Hepatitis B at the EASL Congress 2024. The HBV003 trial showed promising results with 67% of participants having HBsAg <10 IU/mL and 19% with undetectable HBsAg. In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, VTP-300 treatment showed a statistically significant difference in HBsAg levels compared to placebo, with 84% of participants discontinuing standard NUC therapy.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 3:16 pm

FLYE

Fly-E Group shares have resumed trading after a temporary halt. The company is expected to see increased volatility in the short term as investors react to the news.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 3:16 pm

VRNT

Verint Systems shares are trading higher after the company reported better-than-expected Q1 financial results and issued strong FY25 guidance.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 3:15 pm

FLYE

Fly-E Group shares were halted on a circuit breaker due to a significant upward movement in the stock price.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 3:11 pm

FLYE

Fly-E Group's IPO is priced at $4 per share for 2.25 million shares, despite an initial indication of $5.50.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 3:10 pm